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Abstract
Background: Finasteride is a competitive inhibitor of 5 alpha-reductase enzyme, and is used for
treatment of benign prostatic hyperplasia and androgenetic alopecia. Animal studies have shown
that finasteride might induce behavioral changes. Additionally, some cases of finasteride-induced
depression have been reported in humans. The purpose of this study was to examine whether
depressive symptoms or anxiety might be induced by finasteride administration.
Methods: One hundred and twenty eight men with androgenetic alopecia, who were prescribed
finasteride (1 mg/day) were enrolled in this study. Information on depressed mood and anxiety was
obtained by Beck Depression Inventory (BDI), and Hospital Anxiety and Depression Scale (HADS).
Participants completed BDI and HADS questionnaires before beginning the treatment and also two
months after it.
Results: Mean age of the subjects was 25.8(± 4.4) years. At baseline, mean BDI and HADS
depression scores were 12.11(± 7.50) and 4.04(± 2.51), respectively. Finasteride treatment
increased both BDI (p < 0.001) and HADS depression scores significantly (p = 0.005). HADS
anxiety scores were increased, but the difference was not significant (p = 0.061).
Conclusion: This preliminary study suggests that finasteride might induce depressive symptoms;
therefore this medication should be prescribed cautiously for patients with high risk of depression.
It seems that further studies would be necessary to determine behavioral effects of this medication
in higher doses and in more susceptible patients.
Background
Many cases of drug induced depression have been
reported, specially amongst patients who are more suscep-
tible for the disease. Drugs such as corticosteroids, Inter-
feron Alpha, Angiotensin converting enzyme inhibitors
and Calcium channel blockers are all apt to induce some
depressive effects [1]. As depression and anxiety are
important factors, concerning the quality of life and indi-
viduals' health [2], it is important to determine if any psy-
chological or behavioral changes would occur with the
prescription of a particular medication.
Finasteride, a potent 5alpha-reductase inhibitor, has been
approved by Food and Drug Administration (FDA) in
December 1997 for treatment of androgenetic alopecia in
men [3]. The largest application of finasteride consists in
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treating benign prostate hyperplasia which is non-malig-
nant enlargement of the prostate gland that leads to blad-
der out flow obstruction. In women finasteride has been
used in some control trials for treatment of hirsutism [4].
Androgenetic alopecia or male pattern baldness is a com-
mon disorder affecting both men and women. However,
the incidence is generally considered to be greater in male
than female, and the pattern of hair loss differs between
these two genders [5,6]. Finasteride, having a prominent
therapeutic effect in men is used nowadays in a large scale
for the treatment of the disease. Dose-ranging studies sug-
gest the optimal dose of 1 mg per day. Whereas the patient
may respond the treatment in a period of 3 to 4 months,
but the treatment should be continued for at least 12
months before evaluating its complete efficacy [7]. In case
of successful result, the medication is suggested to be used
indefinitely for a long term. The disease begins to progress
gradually when the treatment is stopped [3].
Pharmacologically, Finasteride inhibits 5alpha-reductase,
the converting enzyme of testosterone to dihydrotesto-
sterone (DHT) in many organs, such as prostate and hair
follicles. Both androgenetic alopecia and benign prostate
hyperplasia are androgen dependent disorders and associ-
ated with in situ high levels of intracellular DHT and
increased 5alpha-reductase activity. As androgenic stimu-
lation contributes to pathogenesis of both disorders, fin-
asteride evokes a good therapeutic response by DHT
suppression [8].
Steroid hormones, including androgens undergo an
extensive metabolism in the brain. Several enzymes such
as 5alpha-reductase, 3alpha-hydroxysteroid dehydroge-
nase (3alpha-HSD) and 17beta-hydroxysteroid dehydro-
genase (17beta-HSD) intervene in brain androgen and
steroid metabolism [9,10]. The substances synthesized by
these enzymes affect not only sexual differentiation and
behavior, but also non reproductive functions of the brain
[11,12].
Animal studies suggested that finasteride could alter
5alpha-reductase activity in some regions of the brain,
and lead to behavioral and mood changes. It has been
shown that finasteride is able to inhibit 5alpha-reductase
in medial basal hypothalamus in pregnant rats, and
induce behavioral changes [13]. Significant inhibition of
hypothalamic and pituitary 5alpha-reductase is also
noticed in adult male rats [14]. In addition to animal
studies, although there are some case reports suggesting
finasteride induction of depressive symptoms and anxiety
in humans, [15] but no prospective study has been carried
out, in order to investigate finasteride behavioral effects.
In the present study, we have investigated any depressive
symptoms or anxiety induced by finasteride administra-
tion, in the patients with diagnosis of androgenetic alo-
pecia.
Methods
The study was approved by ethics committee of Tabriz
University of Medical Sciences, Tabriz, Iran. The subjects
were 20 to 38 years old men referred to Sina's dermatol-
ogy clinic, a university affiliated educational center
between January 2004 and December 2004. There was no
age limitation for the subjects. Diagnosis of androgenetic
alopecia was established by a dermatologist. After screen-
ing, 174 men who were prescribed finasteride 1 mg/day
participated in a before-after study.
Patients with history of definitely diagnosed mood disor-
der and any chronic disease with exception of androge-
netic alopecia (specially diseases which are associated
with behavioral changes such as diabetes, hypothy-
roidism and asthma) were excluded from the study.
Patients using other medications at the beginning of treat-
ment, and those who had used some in the period of 10
days before the study, were excluded as well. In addition,
patients with history of medication usage for more than
21 days in the last three months before the study were not
included in the investigation.
All subjects were explained the study process. In addition,
all participants gave informed consent for the study. Con-
tact information collected before the interview and during
consent assignment. A standardized interview was used to
obtain information on age, existence of any defined mood
disorder or other diseases and history of medication use
(systemic or topical).
Information on depressed mood was acquired using
translated and validated Persian versions of Beck Depres-
sion Inventory (BDI) and Hospital Anxiety and Depres-
sion Scale (HADS) [16]. HADS translated and validated
version is used for assessment of anxiety as well.
BDI has 21-item, self-administered inventory, and the
score of each item ranges between 0 and 3. The score of ≤
9 is considered to be within normal range, a score of 10–
15 shows minimal depressive state, a score of 16–31 and
32–47 indicates mild and moderate depression respec-
tively, and a score of > 47 exhibits severe depression.
HADS has 14-item, self-administered questionnaire.
Seven items is related to anxiety, and the other seven,
relates to depression. It has been shown that the HADS is
a valid test not only in hospital practice, but in primary
care and general population as well. Each question has 4
possible responses which are scored from 0 to 3. The two
subscales, anxiety and depression have been found toBMC Clinical Pharmacology 2006, 6:7 http://www.biomedcentral.com/1472-6904/6/7
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independent measures [17]. Both anxiety and depression
score is divided into four ranges: normal (0–7), mild (8–
10), moderate (11–15), and severe (16–21).
First copy of BDI and HADS was completed by each par-
ticipant at the beginning of the study, before finasteride
treatment. The patients were informed about the fact that
the effects of their medication would appear about 3 to 4
months or even more after the treatment onset, in order to
avoid the depressive effects of apparent treatment failure
in the first months. All patients were treated with finas-
teride 1 mg/day (Propecia 1 mg tablets, Merck Sharp &
Dohme Ltd., UK), and asked to record if any other medi-
cation used in the period of the study in a diary.
The subjects were asked to complete both BDI and HADS
questionnaires, two months after the treatment. At the
same time, any extra medications, which had been
recorded in the diary, was checked, and the patients were
asked about any noticeable problems during the treat-
ment. Patients showing with positive history of other
medications were excluded also, except for those who had
used Acetaminophen, Adult Cold, Aluminum Mg, and
Aluminum MgS for less than 5 days.
The statistical analysis was performed by SPSS software
version 11.5 (SPSS Inc. Chicago, IL). We used student's
paired t test for comparing the means before and after the
treatment. Mann-Whitney U test was used to compare the
scores of patients who reported any side effects with oth-
ers.
Results
After interview, 144 eligible men were entered into the
study. Nine patients excluded during the study because of
having extra medication use, with seven others who
refused to complete BDI or HADS.
One hundred and twenty eight men participated in the
study completely. The mean age (± SD) was 25.8 ± 4.4
years. The mean BDI and HADS depression scores are
listed in Table 1. According to the BDI scores at the begin-
ning of the treatment, 46.9% of the subjects were within
normal range, whereas 31.3%, 18.0% and 3.9% were
within minimal depressive, mild depression and moder-
ate depression range, respectively. There was no one
within severe depression range.
The mean ± SD of BDI score was 12.11 ± 7.50 and 12.80
± 7.64 before and after the treatment, respectively. Analy-
sis performed by paired t test, rejected the null hypothesis
of no difference between the means after and before the
treatment, and the BDI scores were significantly increased
after treatment with finasteride 1 mg/day (p < 0.001). The
95% confidence interval, for the difference in the means
of after and before treatment BDI scores, was ranging from
0.34 to 1.04.
We analyzed HADS depression scores as well. The mean ±
SD of HADS-D score was 4.04 ± 2.51 and 4.61 ± 3.19,
before and after the treatment. Analysis using paired t test,
revealed that the HADS-D scores were also significantly
increased 2 months after the treatment.
The mean ± SD of the HADS anxiety score was 6.24 ± 3.17
before the treatment which was increased to 6.60 ± 3.06
(Table 1), but the difference was not significant when
means were compared using paired t test (p = 0.061).
Based on the HADS anxiety scores at the beginning of the
treatment, 60.9% of patients were within normal range,
whereas 28.9% and 10.2% were within mild and moder-
ate range, respectively. There was no one with severe anx-
iety, based on the HADS scores (Table 2).
Two month after the treatment, patients didn't report any
side-effects, except for transient libido loss. Loss of libido
was reported by 9.4% (12 patients) of the subjects. This
was found to be transient and partial in all cases.
We compared BDI and HADS scores of the patients who
complained of libido loss, with those who didn't report
any side effects. Both before and after treatment scores
compared by Mann-Whitney U test between two groups
of libido loss positive and negative patients. No signifi-
cant difference was found between the two groups (Table
3).
Discussion
Testosterone, the main androgenic hormone, is converted
by 5alpha-reductase to DHT in many tissues, which binds
much more avidly with androgen receptor. Two isoforms
of 5alpha-reductase with distinct tissue distribution have
been cloned: 5alpha-reductase type1 and type2. 5alpha-
reductase type1 is widely distributed in the body, whereas
in androgen dependent structures such as prostate, and
hair follicles of scalp DHT is mainly formed by 5 alpha-
reductase type2. However, according to some studies this
isoform is present in many other organs, such as pyrami-
dal cells of cerebral cortex, hepatocytes and bile duct cells.
[18,19].
After binding to the androgen receptor, DHT results in
stimulation of transcription and protein synthesis. In
Table 1: Comparison of BDI and HADS scores
Before treatment After treatment Sig.
BDI 12.11 (± 7.50) 12.80 (± 7.64) < 0.001
HADS-D 4.04 (± 2.52) 4.61 (± 3.19) 0.005
HADS-A 6.24 (± 3.17) 6.60 (± 3.06) 0.061BMC Clinical Pharmacology 2006, 6:7 http://www.biomedcentral.com/1472-6904/6/7
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spite of genomic response, the existence of cell membrane
sex steroid receptors was also suggested recently. These
receptors exist specially in the brain, and provoke rapid
responses [20].
5alpha-reductase is a critical enzyme in the conversion of
several steroids such as testosterone, progesterone, aldos-
terone and corticosterone in the brain. This enzyme con-
verts testosterone to the most natural potent androgen
DHT, and also it acts an important role in conversion of
progesterone to dihhydroprogesterone (DHP). DHP is
further converted to allopregnanolone (5alpha, 3alpha-
tetrahydroprogesterone) by 3alpha-HSD [9,21]. Allopreg-
nanolone is a modulator of gamma amino butyric acid
type A receptor (GABA-A), and increases chloride con-
ductance. This neurosteroid has been found to exert anti-
convulsant, anesthetic and anxiolytic effects [22-24].
Moreover, change in the levels of allopregnanolone is
found to be associated with depressive disorders. [25,26]
Our results are in agreement with the past published
reports [15], and indicate that finasteride might induce
depressive symptoms. The 95% confidence interval, for
the difference in the means of the BDI scores, was ranging
from 0.34 to 1.04. This shows that the overall change
induced by finasteride is minimal, but statistically signifi-
cant. Anxiety scores were also increased, but the difference
was not significant.
A decline in serum DHT level occurs after finasteride
administration [27]. This may contribute to finasteride
induced depression. Some studies have been shown that
serum DHT level, which is in equilibrium with the brain
[28], is inversely associated with depression. A study by
Barrett-Connor E. et al. showed that BDI scores were
inversely associated with bioavailable testosterone and
DHT level [29]. Furthermore, it was found that DHT had
anti-depressant effects on behavior of male rats and its
replacement in castrated rats was able to partially decrease
the immobility behavior, which is indicative of depres-
sion [30].
Finasteride induced psychiatric dysfunction can also be
attributed to its inhibitory effect on androgen and steroid
5alpha-reduction in the brain. Animal studies suggest that
finasteride has inhibitory effects on 5alpha-reduction of
testosterone and progesterone in the brain and inhibits
the formation of allopregnanolone [31,32]. Allopregna-
nolone has an important role in depressive disorders [26].
In 1998 Romeo E. et al, revealed that episodes of unipolar
major depressive disorder in men is associated with a
decline in the plasma concentrations of allopregnanolone
[25]. Furthermore, a study carried out by Uzunova V. et al.
showed that CSF levels of allopregnanolone were signifi-
cantly lower in depressed patients, and there was negative
correlation between allopregnanolone levels in CSF and
HAM-D scores. [33].
Since finasteride is a potent 5AR type2 inhibitor and the
predominant isoform of the enzyme in human brain is
5AR type1 [34,35], some points should be noted concern-
ing finasteride inhibitory effect on brain steroid metabo-
lism. (i) Although finasteride is a potent 5AR type2
inhibitor, but it has also some inhibitory effects on 5AR
type1 [36]. (ii) Finasteride administration in humans has
been reported to be associated with some behavioral and
mental disorders related to low levels of allopregna-
nolone in the brain [37]. This may also improve the con-
cept of brain allopregnanolone suppression by finasteride
in humans.
However, from the current study, it can not be concluded
that the pathophysiology of finasteride-induced mood
disorder is attributable to any of the mentioned material.
We couldn't find any significant change in the anxiety
scores before and after the treatment (p = 0.061). Accord-
ing to the anxiolytic effects of allopregnanolone and tes-
tosterone [38-40], it seems that further investigations with
a larger sample size are necessary to determine whether
finasteride administration is associated with anxiety.
Table 3: Scores compared between two groups of libido loss 
positive and negative patients
Sig.
BDI Before treatment 0.73
HADS-D Before treatment 0.61
HADS-A Before treatment 0.42
BDI After treatment 0.94
HADS-D After treatment 0.45
HADS-A After treatment 0.30
Table 2: Individuals in different depression categories measured 
by BDI and HADS-A
Depression categories N Percent Mean (± SD)
Normal 60 46.9 6.47 (± 2.14)
Minimal depressive 40 31.3 12.20 (± 1.70)
symptoms 23 18.0 22.26 (± 4.25)
Mild depression 5 3.9 32.60 (± 0.55)
Moderate depression 00
Severe depression 00
Anxiety categories N Percent Mean (± SD)
Normal 78 60.9 3.99 (± 2.14)
Mild anxiety 37 28.9 8.95 (± 0.78)
Moderate anxiety 13 10.2 12.08 (± 0.95)
Sever anxiety 00BMC Clinical Pharmacology 2006, 6:7 http://www.biomedcentral.com/1472-6904/6/7
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Finasteride associated side effects were reported by 9.4%
of patients in this study. In all cases, the reported side
effect was transient and partial libido loss. This side effect
was reported by several studies and in different incidences
[3,41]. Despite the fact that male sexual function and
behavior is related to sex hormone metabolism [42], we
couldn't find any relation between libido loss and BDI
nor HADS score, before and after the treatment. This may
be caused by the sample size effect as there were just 12
subjects in side effect positive group.
Some limitations concerning the study should be raised.
The present study didn't have any control group. Exclud-
ing the subjects with definitely diagnosed other diseases
or positive history of mood disorder, might result in miss-
ing some individuals with a high risk for behavioral
changes. However, as a preliminary study, we had to
exclude these patients to avoid any confounding effects
on the results.
Conclusion
In conclusion, this preliminary study suggests that finas-
teride might induce depressive symptoms. Although our
data suggest a slight change, the side effect should be con-
sidered specially when the medication is prescribed for
patients, who are more susceptible for it.
Finally, we recommend that further studies should be per-
formed to elucidate behavioral effects of finasteride in
higher doses and in high risk groups such as elderly
patients.
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